» Articles » PMID: 16175402

Timing of Nicotine Effects on Learning in Zebrafish

Overview
Specialty Pharmacology
Date 2005 Sep 22
PMID 16175402
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Nicotine has been shown in many, but not all, studies to improve cognitive function in a number of species including rats, mice, monkeys, and humans. Recently, we have found that nicotine also improves memory in zebrafish. Nicotinic agonists are being developed as novel treatments for Alzheimer's disease and other cognitive impairments.

Objectives: In screening the therapeutic potential of novel nicotinic agonists, it is important to have a rapid assay of cognitive improvement. Zebrafish can help with this effort.

Methods: We have developed a method of rapidly assessing spatial position discrimination learning in zebrafish in one session of seven trials. We used this method to determine the cognitive effects of nicotine.

Results: Nicotine (100 mg/l administered during 3 min of immersion) caused a significant improvement in percent correct performance. This dose was within the effective range we found to improve the choice accuracy performance of zebrafish using the more time-intensive delayed spatial alternation procedure. Interestingly, the positive effect of nicotine was seen at 20-40 min postadministration, but not earlier, and declined at 80 and 160 min posttreatment. At the 40-min postdosing interval, 200 mg/l nicotine was also found to significantly improve choice accuracy. Nicotine-induced accuracy improvement was reversed by the nicotinic antagonist mecamylamine given shortly before testing but not when given concurrently with nicotine.

Conclusions: This position discrimination procedure in zebrafish effectively demonstrated the cognitive-enhancing effects of nicotine. This model may be useful in the early screening of novel nicotinic compounds for treatment of cognitive dysfunction.

Citing Articles

Neonicotinoid Imidacloprid Affects the Social Behavior of Adult Zebrafish by Damaging Telencephalon Neurons through Oxidation Stress, Inflammation, and Apoptosis.

Chung K, Chen L, Tseng H, Wu C Life (Basel). 2023; 13(6).

PMID: 37374200 PMC: 10304127. DOI: 10.3390/life13061418.


A gelatin-based feed for precise and non-invasive drug delivery to adult zebrafish.

Ochocki A, Kenney J J Exp Biol. 2023; 226(2).

PMID: 36606734 PMC: 10165467. DOI: 10.1242/jeb.245186.


Zebrafish: A Pharmacological Model for Learning and Memory Research.

Tan J, Nazar F, Makpol S, Teoh S Molecules. 2022; 27(21).

PMID: 36364200 PMC: 9657833. DOI: 10.3390/molecules27217374.


Exploring Neurobehaviour in Zebrafish Embryos as a Screening Model for Addictiveness of Substances.

Havermans A, Zwart E, Cremers H, van Schijndel M, Constant R, Meskovic M Toxics. 2021; 9(10).

PMID: 34678946 PMC: 8539716. DOI: 10.3390/toxics9100250.


Anxiolytic, Promnesic, Anti-Acetylcholinesterase and Antioxidant Effects of Cotinine and 6-Hydroxy-L-Nicotine in Scopolamine-Induced Zebrafish () Model of Alzheimer's Disease.

Boiangiu R, Mihasan M, Gorgan D, Stache B, Hritcu L Antioxidants (Basel). 2021; 10(2).

PMID: 33535660 PMC: 7912787. DOI: 10.3390/antiox10020212.


References
1.
Loucks E, Carvan 3rd M . Strain-dependent effects of developmental ethanol exposure in zebrafish. Neurotoxicol Teratol. 2004; 26(6):745-55. DOI: 10.1016/j.ntt.2004.06.017. View

2.
Buccafusco J, Jackson W . Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging. 1991; 12(3):233-8. DOI: 10.1016/0197-4580(91)90102-p. View

3.
Rozin P . TEMPERATURE INDEPENDENCE OF AN ARBITRARY TEMPORAL DISCRIMINATION IN THE GOLDFISH. Science. 1965; 149(3683):561-3. DOI: 10.1126/science.149.3683.561. View

4.
Gentry C, Lukas R . Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr Drug Targets CNS Neurol Disord. 2003; 1(4):359-85. DOI: 10.2174/1568007023339184. View

5.
Newhouse P, Potter A, Levin E . Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging. 1997; 11(3):206-28. DOI: 10.2165/00002512-199711030-00005. View